Skip to content
Yog Pharma

Sildenafil Citrate is a PDE5 inhibitor indicated for erectile dysfunction and pulmonary arterial hypertension. We supply it to US manufacturers of tablets, oral suspension and injection.

CAS171599-83-0666.7 g/molC28H38N6O11S
2D structure of Sildenafil Citrate, shown as the active moiety without counter-ion or water of hydration.

Data from PubChem (CID 135413523) and FDA’s substance registry

CAS number

171599-83-0

Molecular formula

C28H38N6O11S

Molecular weight

666.7g/mol

FDA UNII

IUPAC name

5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-6H-pyrazolo[4,5-d]pyrimidin-7-one;2-hydroxypropane-1,2,3-tricarboxylic acid

InChIKey

DEIYFTQMQPDXOT-UHFFFAOYSA-N

Appearance
White to off-white crystalline powder.
Solubility
Solubility in water is 3.5 mg/mL.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

Strengths are expressed as sildenafil base. The same API goes into erectile dysfunction tablets and the 20 mg tablets for pulmonary arterial hypertension.

On the US market

Reference product
ViagraNDA 020895
Approved ANDAs
38 with a marketed product
Approved forms and strengths
  • Tablet 20 mg, 25 mg, 50 mg, 100 mg
  • Powder for oral suspension 10 mg/mL
  • Oral film 25 mg, 50 mg, 75 mg, 100 mg
  • Injection 10 mg/12.5 mL

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. Strengths of salt forms are stated as the active moiety. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com